Aracatuba

This research aims to evaluate the safety and effectiveness of BGB-16673 compared to pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously been treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi). The study is a Phase 3, open-label, randomized trial sponsored by BeOne Medicines. The goal is to better understand treatment options for patients whose disease has returned or did not respond to earlier therapies involving cBTKi. Participants will receive either BGB-16673 or pirtobrutinib, both given orally. The study compares these two treatments to assess their safety and efficacy. The treatment period and dosing details are managed as per the trial protocol to evaluate the outcomes of each drug. The study includes ongoing monitoring and assessments to observe treatment effects over time. During the study, participants will be closely followed for up to approximately 3 years to measure progression-free survival, as assessed by an independent review committee. Researchers will conduct regular evaluations including imaging and laboratory tests to track disease status and safety. Participants' health will be monitored throughout the study to identify any side effects or changes in condition.

Researchers are evaluating the effectiveness of DYNAVISC in people diagnosed with persistent or recurrent carpal tunnel syndrome. This prospective, multicenter, randomized, evaluator-blinded clinical trial compares two methods of covering the median nerve after revision surgery: standard surgery followed by DYNAVISC application, and standard surgery followed by coverage with a hypothenar fat pad flap. The study aims to understand how these approaches affect pain and nerve recovery. Participants will be randomly assigned to one of two groups: one receiving DYNAVISC applied around the median nerve after surgery, and the other receiving coverage of the median nerve with a hypothenar fat pad flap. Following surgery, all participants will gently move their wrist and fingers several times daily, with strenuous movements allowed after six weeks. The hand will be checked at 1 week, 4 weeks, and 12 weeks after surgery. During the study, participants will record their pain levels using a visual analog scale (VAS), hand function will be assessed with the Quick DASH score, and neuropathic pain will be measured with the DN4 score. Median nerve recovery will be evaluated by electroneuromyography, and grip strength will be tested with a dynamometer. These assessments will be done at the start and during follow-up visits by individuals unaware of the treatment received. The main outcome measured is pain at 12 weeks post-surgery.